Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development.For every commercial-stage drug out there that generates millions and sometimes billions in annual sales, there were thousands of new drug candidates that didn't get across the finish line. You don't need a life-science background to see an opportunity to streamline this process with help from artificial intelligence (AI) and new automation techniques.Recursion Pharmaceuticals (NASDAQ: RXRX) has gained a lot of attention in recent years with an AI-powered drug-discovery platform that aims to reduce the amount of trial and error that's required to discover successful new drug candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool